171P Combining tumor-infiltrating lymphocytes and PD-L1 expression can stratify prognosis in early-stage triple-negative breast cancer patients who did not receive adjuvant chemotherapy

Abstract

Listen

Translate article

In early-stage triple-negative breast cancer (TNBC), stromal tumor-infiltrating lymphocytes (sTILs) are an independent prognostic factor. Further prognostic stratification may be possible by combining immune biomarkers including tertiary lymphoid structure (TLS) and PD-L1 expression in addition to TILs. Here, we evaluated the association of sTILs, PD-L1, and TLS with prognosis in TNBC not receiving chemotherapy.